Advertisement
Canada markets close in 1 hour 11 minutes

  • S&P/TSX

    21,875.82
    +2.10 (+0.01%)
     

  • S&P 500

    5,034.59
    -37.04 (-0.73%)
     

  • DOW

    37,986.67
    -474.25 (-1.23%)
     

  • CAD/USD

    0.7318
    +0.0021 (+0.28%)
     

  • CRUDE OIL

    83.53
    +0.72 (+0.87%)
     

  • Bitcoin CAD

    88,199.41
    +216.86 (+0.25%)
     

  • CMC Crypto 200

    1,394.09
    +11.52 (+0.83%)
     

  • GOLD FUTURES

    2,343.60
    +5.20 (+0.22%)
     

  • RUSSELL 2000

    1,976.54
    -18.88 (-0.95%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,557.66
    -155.08 (-0.99%)
     

  • VOLATILITY

    16.33
    +0.36 (+2.26%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6819
    0.0000 (0.00%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, DOWNBEAT GDP

Caterpillar sinks 7% after earnings, management sees weakness in Europe, Asia-Pacific

Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference

Celldex Therapeutics, Inc.
·1 min read

HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 pm ET.

A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for fourteen days following the event.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com